IMRT 2018

Conclusions

• Ideally, in-vivo plan verification should be performed for all techniques • IMRT potentially pushes the delivery- and planning equipments to their limits • Confidence in the whole chain should be built through patient-specific pre- treatment plan verification • Convenient ’IMRT QA’ systems exist • Gamma analysis is useful for a high-throughput QA programme • Limitations of the gamma index require attention to dose deviation in selected cases • Consider patient-specific QA as one among several important components of the QA programme

06/06/2018